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Summary
Background Colorectal cancer (CRC) is the fourth
most common cause of death worldwide. Approxi-
mately 30% of all CRC occurs in the rectum. Improve-
ments in survival rates were achieved thanks to mul-
timodal therapy, combining surgery and chemoradia-
tion. Nevertheless, the prognosis of patients suffering
from rectal cancer (RC) remains poor. Programmed
cell death protein 1 (PD-1) and its ligand programmed
death ligand 1 (PD-L1) regulate tumor immune re-
sponse. The aim of this study was to analyze the
expression of PD-L1 in RC pre- and post-neoadju-
vant therapy and evaluate PD-L1 as a biomarker and
potential target for therapy.
Methods In all, 29 patients with RC treated at the
Medical University Vienna who received preoperative
chemoradiation were retrospectively enrolled in this
study. Expression of PD-L1 was investigated by im-
munohistochemistry with two different anti-PD-L1
antibodies.
Results No PD-L1 expression on cancer cells could
be observed in all 29 cases in the specimens before
chemoradiation as well as in the surgical specimens
after neoadjuvant therapy. In one of the two staining
methods performed, five (17.24%) post-chemoradia-
tion cases showed faint lymphohistiocytic staining.
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Conclusion No expression of PD-L1 in RC cells before
and after chemoradiation was found in our collective
of 29 patients. Further investigations to evaluate the
role of PD-L1 as a potential therapeutic target in RC
are urgently needed.
Keywords Rectal cancer · Programmed death lig-
and 1 · Tumor-infiltrating lymphocytes · Neoadjuvant
chemoradiation · Total mesorectal excision
Introduction
Colorectal cancer (CRC) is one of the leading causes
of cancer-related death worldwide [1]. The standard
treatment of locally advanced rectal cancer (RC) is
neoadjuvant chemoradiation (NCR) followed by sur-
gical resection [2]. Despite the usage of multimodal
neoadjuvant therapy and improved survival rates, the
prognosis of patients with RC remains unsatisfying.
After neoadjuvant treatment combined with surgi-
cal resection, histopathological response rates differ
enormously [3]. In recent years, significant insights
into the interactions between the immune system and
cancer cells have been gained. Recently, programmed
death ligand 1 (PD-L1) raised scientific interest, as the
first clinical studies with PD-L1 inhibitors promised
encouraging results in several tumor types [4–7].
The binding of PD-L1 to its receptor programmed
cell death protein 1 (PD-1) plays a major role in the
interaction between cancer and the immune system.
PD-1 belongs to the CD28/CTLA-4 immunoglob-
ulin family and is expressed on activated T and
B cells, monocytes, and tumor-infiltrating lympho-
cytes (TILs). PD-L1 can be found on resting T cells,
B cells, macrophages, and vascular endothelial cells
[8, 9]. The PD-1–PD-L1 interaction plays a key role in
maintaining self-tolerance to protect against severe
self-damage while the immune system is activated be-
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cause of infections. Tumor cells can overexpress PD-
L1, which binds to PD-1 on T cells and inhibits their
activation. As a result, the tumor escapes surveillance
by the immune system [10–12].
PD-L1 has been reported to be expressed in a num-
ber of malignancies, especially by glioblastoma, non-
small-cell lung cancer, melanoma, renal cell carci-
noma, and esophageal cancer [13–17]. Although PD-
L1 is present in the cytoplasm and on the plasma
membrane of tumor cells, not every type of cancer ex-
presses PD-L1 [8, 18]. Clinical trials report promising
data, when investigating PD-1 and/or PD-L1 block-
ade using monoclonal antibodies. Nevertheless, only
a small number of patients benefit from inhibiting PD-
1 or PD-L1 [7, 19, 20].
Recently, a difference in expression of PD-L1 in
post-neoadjuvant therapy tumor tissue compared
with pre-neoadjuvant therapy tumor tissue was found
for various cancers [21–23]. To date, the expression
of PD-L1 in neoadjuvant-treated RC has not been
investigated intensively. In this single-center study,
we examined the effect of neoadjuvant treatment on
the expression of PD-L1 of locally advanced RC.
Material and methods
Patients
In this retrospective analysis all patients underwent
surgery for RC at the Department of Surgery, Medical
University of Vienna, between 1 January 2012 and
31 December 2013. The study was approved by the
Ethics Committee of the Medical University of Vienna,
Austria, according to the Declaration of Helsinki. The
study population consisted of patients who under-
went total mesorectal excision (TME) after receiv-
ing capecitabine-based neoadjuvant chemoradia-
tion (NCR) at the University Hospital Vienna, Austria
(Fig. 1). Chemoradiation was delivered as long-course
radiation (LCRT) with 50.4 Gy (1.8 Gy in 28 fractions).
Fig. 1 aTotalmesorectal excisionspecimen.b * Rectal cancer after neoadjuvant chemoradiation showingareasof fibrosis indicat-
inggood response
Patients presenting with distant metastatic disease at
the time of diagnosis were excluded from the analysis.
PD-L1 expression in the context of NCR was inves-
tigated on pre-NCR biopsies and post-NCR surgical
specimens. The clinicopathological factors selected
and analyzed were age, gender, TNM staging accord-
ing to the Union Contre le Cancer (UICC) 7th edition
TNM classification, and the response rate to NCR [24].
Assessment of response to NCR
Post-NCR specimens were analyzed for tumor re-
sponse to neoadjuvant treatment. Response to neoad-
juvant chemoradiation is reported as the ratio of vi-
able tumor tissue and fibrosis. Tumor response rates
were analyzed according to Dworak et al. [25]. Re-
sponse was graded as: 0 – no regression; 1 – dominant
tumor mass with obvious fibrosis and/or vasculopa-
thy; 2 – dominantly fibrotic changes with few tumor
cells or groups; 3 – very few (difficult to find mi-
croscopically) tumor cells in fibrotic tissue with or
without mucous substance; 4 – no tumor cells, only
fibrotic mass (total regression or response).
Immunohistochemistry
Immunohistochemistry (IHC) was performed on
paraffin-embedded specimens fixed in 4% buffered
formalin, using 3-µm-thick histological sections. For
PD-L1 expression in pre- and post-NCR tissue, two
different staining methods were used. The first stain-
ing method was performed on a Ventana® BenchMark
ULTRA (Roche, Tucson, AZ), automated IHC slide
staining system, using the universal DAB detection
kit with cell conditioning 1 (CC1) buffer of pH 8 and
the PD-L1 (E1L3N®) XP® rabbit mAb (Cell Signalling
Technology, Danvers, MA).
The second staining method was performed manu-
ally, using the antibody 5H1 (monoclonal antibody of
human B7H1, Dr. Lieping Chen’s lab, isotype: mouse
IGg1) as described previously [18].
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Age (years) n =29
Median age 65 (23–85) – – –
Male 24 (82.76) – – –
Female 5 (17.24) – – –
– pre-NCR (n = 29) post-NCR (n = 29)
Tumor grading (%)
G2 24 (82.76) G2 17 (58.63)
G3 5 (17.24) G3 7 (24.13)
Gx 0 (0) Gx 5 (17.24)
Tumor stage (%)
cT0 0 (0) ypT0 3 (10.35)
cT1 0 (0) ypT1 2 (6.90)
cT2 1 (3.45) ypT2 8 (27.57)
cT3 22 (75.86) ypT3 14 (48.28)
cT4 6 (20.69) ypT4 2 (6.90)
Lymph node status (%)
cN0 9 (31.03) ypN0 19 –
cN1 6 (20.69) ypN1 7 (24.13)
cN2 14 (48.28) ypN2 3 (10.35)
UICC stage (%)
0 0 (0) – 3 (10.35)
I 1 (3.45) – 9 (31.03)
II a 7 (24.13) – 7 (24.13)
II b 1 (3.45) – 0 (0)
III a 0 (0) – 1 (3.45)
III b 6 (20.69) – 6 (20.69)
III c 14 (48.28) – 3 10,35
Response ratea to NCR (%)
4 – – – 3 (10.35)
3 – – – 15 (51.72)
2 – – – 4 (13.79)
1 – – – 3 (10.35)
0 – – – 4 (13.79)
NCR neoadjuvant chemoradiation, UICC Union Contre le Cancer
aAccording to Dworak et al.
PD-L1 expression was scored as positive or neg-
ative with semiquantitative estimation of percentage
of positive tumor and stroma cells. Slides stained ac-
cording to the first staining method were indepen-
dently reviewed and scored by two observers (M.L.
and J.G.). All slides stained according to the second
staining method were reviewed and scored by M.B.
Statistical analysis
Correlations between clinicopathological factors and
expression of PD-L1 were analyzed with the χ2 test
or Fisher’s exact test. Statistical analyses were per-
formed, using SPSS 21.0 (IBM Corp.©, SPSS©) software.
Table 2 Pre-andpost-NCRexpressionofPD-L1 inall
29cases, using twodifferent antibodies for staining
Expression of PD-L1 before and after NCR
Factor Antibody E1L3N Antibody 5H1
(n = 29) (%) (n =
29)
(%)
PD-L1 expression tumor pre-NCR
0 29 (100) 29 (100)
1 0 (0) 0 (0)
2 0 (0) 0 (0)
3 0 (0) 0 (0)
PD-L1 expression stroma pre-NCR
0 29 (100) 29 (100)
1 0 (0) 0 (0)
2 0 (0) 0 (0)
3 0 (0) 0 (0)
PD-L1 expression tumor post-NCR
0 29 (100) 29 (100)
1 0 (0) 0 (0)
2 0 (0) 0 (0)
3 0 (0) 0 (0)
PD-L1 expression stroma post-NCR
0 24 (82.76) 29 (100)
1 5 (17.24) 0 (0)
2 0 (0) 0 (0)
3 0 (0) 0 (0)
NCR neoadjuvant chemoradiation
Results
The final study population consisted of 29 patients
(82.76% males and 17.24% females), who were eli-
gible for further investigations. Overall median age
at the time of surgery was 65 years (23–85 years).
The majority of patients (68.97%) were radiologically
in advanced UICC stages at the time of diagnosis
(Table 1).
All study patients received LCRT and completed
NCR.
The histopathological results of the surgical speci-
mens showed three patients (10.34%) with complete
response (CR, grade 4), 22 patients (75.86%) with
partial response (PR, grades 3–1), and four patients
(13.8%) with no response to NCR at all (nonrespon-
ders, NR; details in Table 1).
For both immunohistochemical staining methods
employed, no expression of PD-L1 on neoplastic cells
could be detected in all pre-NCR (29 cases, 100%),
as well as in all post-NCR cases (29 cases, 100%). In
five post-NCR cases (17.24%) stained according to the
first staining method, faint lymphohistiocytic staining
(intensity score 1) of TILs could be observed (Fig. 2).
Two of those five cases showed CR, two PR, and one
was NR (Table 2).
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Fig. 2 a–cRepresentativehematoxylin–eosin(H&E)-stainedrectalcancer (RC)specimensafterneoadjuvantchemoradiation(NCR)




Even after adequate surgery, still around 30% of pa-
tients with RC suffer from metastatic disease within
5 years of surgery. Currently established adjuvant
chemotherapeutic agents have limited potential to
prevent recurrence [2, 3]. Alternative treatment op-
tions are currently tested in clinical trials to improve
long-term outcome [26].
Immunotherapy offers new opportunities in can-
cer treatment. Anti-PD-L1 antibodies showed encour-
aging results in different cancer patients, especially
melanoma and recently non-small-lung cancer [19,
20]. In comparison with standard treatment, using
chemo- and/or radiotherapy, immunotherapy is rel-
atively safe, effective, and has low-grade side effects.
Consecutively, this treatment modality gained high in-
terest in CRC, too [27, 28].
Recently, Droeser et al. analyzed nearly 1,500 CRC
samples, showingmore than 30% PD-L1 expression in
untreated tumor tissue [29]. In contrast to other can-
cer types [21, 22], limited data are published on PD-
L1 expression in RC and a potential impact of neoad-
juvant therapy on PD-L1 expression. Therefore, the
aim of this study was to investigate the expression of
PD-L1 in a cohort of 29 neoadjuvant treated-patients
suffering from locally advanced CRC.
Unfortunately, we could not detect PD-L1 expres-
sion neither in pre-NCR nor in post-NCR tumor tis-
sues. Nevertheless, we observed expression of PD-L1
on TILs, which are considered to represent the im-
mune response of the host to a malignant tumor, in
five post-NCR cases. Expression of PD-L1 in 17.24% of
post-NCR TILs might implicate that the PD-L1/TAM
(tumor-associated macrophages) and PD-1/TIL path-
way is activated.
The significantly higher rate of PD-L1 expression
in the study by Droeser et al. might be explained
by a different study population combining patients
with colon cancer and RC. We know from Xiao and
Freedman that a microsatellite instable (MSI) subset
of CRC might be a promising target for checkpoint im-
munotherapy [30]. Although Devaraj et al. reported
that MSI in RC is rare, to our knowledge, little is known
about the expression of PD-L1 in an MSI subset of RC
to date [31].
Therefore, even though Droeser et al. reported
more than 30% PD-L1 expression in CRC tumor tis-
sue, further investigations in developing PD-L1/PD-
1 based immunotherapy should focus on the cell-
type-specific analysis of the tumor surrounding the
stroma. As mentioned, an MSI subset of CRC might
be a promising target for checkpoint immunother-
apy [30]. Based on these results, the MSI subset
might be a potential therapeutic target in RC as well.
Therefore, the role of PD-L1 as biomarker or target
in immunotherapy in neoadjuvant-treated RC needs
further investigation.
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